{"product_id":"evolenthealth-swot-analysis","title":"Evolent Health SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEvolent Health stands at the intersection of value-based care and technology, leveraging care-delivery platforms and payer partnerships to drive revenue growth while facing regulatory, competitive, and integration risks; our full SWOT unpacks these dynamics with financial context and strategic recommendations. Discover the complete, editable report—Word and Excel deliverables—to guide investment decisions, pitches, and operational planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Clinical Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvolent Health’s Evolent Specialty platform manages complex areas like oncology and cardiology, covering services that drove 28% of client medical spend in 2024, helping health plans cut avoidable costs by up to 12% per CMS-aligned programs; this focus on high-cost care creates deep clinical protocols and partnerships that form a durable moat, hard for generalist health tech firms to replicate quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Identifi Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Identifi platform acts as a central nervous system for value-based care, ingesting claims, EHR, SDOH and RPM data to deliver actionable insights; Evolent reported Identifi supported care for ~1.6M members in 2024. It spots high-risk patients for early intervention, lowering admissions and driving reported utilization savings of ~6–9% in 2023 pilot programs. Its cloud-native, API-first design shortens onboarding times, letting Evolent add partners faster than manual legacy systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerformance-Based Revenue Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA significant portion of Evolent Health revenue comes from performance-based contracts where it shares in client savings; in 2025 these arrangements accounted for roughly 55% of revenue, up from 47% in 2023. This aligns incentives with health plans and providers, promoting multi-year partnerships and reduced churn. As of Q3 2025, margin expansion is visible—adjusted operating margin rose to 9.8%—driven by more effective clinical interventions and care-management scalability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisition Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvolent Health’s integration of Magellan Specialty Health (acquired 2022) and NIA (2023) expanded its managed specialty care footprint to serve over 10 million lives and increased FY2024 revenue contribution from specialty services to ~28% of total revenue.\u003c\/p\u003e\n\u003cp\u003eThese deals enabled cross-selling across 200+ client relationships and a more complete specialty care management platform, while management reported $45–55M run-rate synergies captured within 12–18 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquisitions: Magellan Specialty Health (2022), NIA (2023)\u003c\/li\u003e\n\u003cli\u003eLives served: \u0026gt;10 million (2024)\u003c\/li\u003e\n\u003cli\u003eSpecialty revenue share: ~28% of FY2024\u003c\/li\u003e\n\u003cli\u003eReported synergies: $45–55M run-rate (12–18 months)\u003c\/li\u003e\n\u003cli\u003eCross-sell reach: 200+ client relationships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Multi-Year Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvolent benefits from multi-year contracts that drove 2024 recurring revenue of about $1.1 billion, giving investors high revenue visibility and lower churn risk.\u003c\/p\u003e\n\u003cp\u003eThese agreements commonly include renewal options and reflect high switching costs from deep workflow integration, with average contract durations often exceeding three years.\u003c\/p\u003e\n\u003cp\u003eSteady cash flow funds R\u0026amp;D—Evolent spent $123 million on R\u0026amp;D in 2024—to sustain its tech edge and product roadmap.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 recurring revenue ~$1.1B\u003c\/li\u003e\n\u003cli\u003eAverage contract \u0026gt;3 years\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend $123M (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolent: Specialty clinical scale, $1.1B recurring, 10M+ lives, 55% performance revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvolent’s strengths: specialty-heavy clinical platform (oncology\/cardiology) driving durable margins; Identifi analytics supporting ~1.6M members and cutting utilization; 55% performance-based revenue (2025) and ~$1.1B recurring revenue (2024) with \u0026gt;10M lives served after Magellan\/NIA; $123M R\u0026amp;D (2024) and $45–55M synergies run-rate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLives served\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003ctd\u003e~$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerformance revenue\u003c\/td\u003e\n\u003ctd\u003e~55% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$123M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynergies\u003c\/td\u003e\n\u003ctd\u003e$45–55M run-rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Evolent Health, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise SWOT snapshot of Evolent Health for quick strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Customer Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA substantial share of Evolent Health’s revenue comes from a few large health-plan partners—about 60% of 2024 revenue tied to the top five clients—so losing one major contract or a large membership segment could cut revenue sharply and hurt margins. \u003c\/p\u003e\n\u003cp\u003eThat client concentration limits Evolent’s bargaining power in renewals and pricing, raising renegotiation risk and potential margin compression if partners demand lower fees or shift services in-house. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe aggressive acquisition push has left Evolent Health with roughly $1.05 billion of long-term debt and reported interest expense near $90 million in FY2024, constraining net income and free cash flow. High interest costs reduce funds for organic growth and capex, and limit agility for further M\u0026amp;A without equity dilution. Management cites deleveraging and refinancing as priorities while navigating rate volatility into 2025, targeting lower net leverage ratios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating at the intersection of technology, clinical services, and admin support raises operational complexity for Evolent Health, requiring integration across 150+ clinical workflows and 25 state regulatory frameworks as of 2025.\u003c\/p\u003e\n\u003cp\u003eManaging diverse specialty workflows demands specialized talent and overhead; SG\u0026amp;A was 17.8% of revenue in 2024, reflecting that burden.\u003c\/p\u003e\n\u003cp\u003eExecution lapses risk reputational damage and fines under value-based contracts—Evolent faced a 2023 performance shortfall that reduced net income by $14.2M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Profitability Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite adjusted EBITDA gains, Evolent Health posted GAAP net losses in 2023 and 2024 driven by $120m+ annual amortization and integration costs tied to acquisitions, masking true cash earnings.\u003c\/p\u003e\n\u003cp\u003eInvestors focus on the widening gap between adjusted EBITDA and GAAP results—adjusted EBITDA of $160m in 2024 vs GAAP net loss of $45m—questioning earnings quality.\u003c\/p\u003e\n\u003cp\u003eThe firm must show repeatable, high-quality GAAP profits as scale matures to relieve valuation pressure and improve investor confidence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 adjusted EBITDA $160m\u003c\/li\u003e\n\u003cli\u003e2024 GAAP net loss $45m\u003c\/li\u003e\n\u003cli\u003e$120m+ annual amortization\/integration\u003c\/li\u003e\n\u003cli\u003eNeed sustained GAAP profitability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Healthcare Enrollment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEvolent Health’s revenue scales with lives managed for partner health plans, so enrollment declines hit top-line growth directly; at year-end 2024 Evolent reported 8.5 million lives under management, down 3% vs. 2023.\u003c\/p\u003e\n\u003cp\u003eReductions in employer-sponsored coverage from higher unemployment or tighter labor markets, and policy shifts cutting Medicaid or Medicare Advantage enrollment, would reduce fees and care-margin revenue.\u003c\/p\u003e\n\u003cp\u003eThis external dependency increases sensitivity to macro swings outside Evolent’s control and raises earnings volatility risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8.5M lives managed (2024 year-end)\u003c\/li\u003e\n\u003cli\u003eRevenue tied per-enrollee fees and value-based contracts\u003c\/li\u003e\n\u003cli\u003eEnrollment declines → direct top-line and margin pressure\u003c\/li\u003e\n\u003cli\u003eVulnerable to unemployment and policy changes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh client concentration, falling lives and heavy debt squeeze profits and boost execution risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh client concentration (~60% of 2024 revenue from top 5 clients) and 8.5M lives (down 3% YoY) raise churn and pricing risk; heavy debt ($1.05B LT debt; ~$90M interest in FY2024) and $120M+ annual amortization squeeze GAAP profits (2024: adjusted EBITDA $160M vs GAAP net loss $45M); complex ops across 150+ workflows and 25 states drive SG\u0026amp;A 17.8% of revenue, increasing execution and regulatory risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 client rev share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLives managed\u003c\/td\u003e\n\u003ctd\u003e8.5M (-3% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLT debt\u003c\/td\u003e\n\u003ctd\u003e$1.05B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense\u003c\/td\u003e\n\u003ctd\u003e~$90M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e$160M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP net loss\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual amortization\/integration\u003c\/td\u003e\n\u003ctd\u003e$120M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e17.8% of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEvolent Health SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is a real excerpt from the complete, editable file. You’re viewing a live preview of the actual SWOT analysis; buy now to unlock the full, detailed version immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752570106233,"sku":"evolenthealth-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/evolenthealth-swot-analysis.png?v=1772242509","url":"https:\/\/matrixbcg.com\/products\/evolenthealth-swot-analysis","provider":"matrixbcg.com","version":"1.0","type":"link"}